Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 334


Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study.

Campo G, Valgimigli M, Gemmati D, Percoco G, Catozzi L, Frangione A, Federici F, Ferrari F, Tebaldi M, Luccarelli S, Parrinello G, Ferrari R.

J Am Coll Cardiol. 2007 Sep 18;50(12):1132-7. Epub 2007 Sep 4.


Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.

Siller-Matula JM, Lang I, Christ G, Jilma B.

J Am Coll Cardiol. 2008 Nov 4;52(19):1557-63. doi: 10.1016/j.jacc.2008.07.055.


Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.

Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2010 Jun 1;55(22):2427-34. doi: 10.1016/j.jacc.2010.02.031.


Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?

Angiolillo DJ, Fernández-Ortiz A, Bernardo E, Barrera Ramírez C, Sabaté M, Fernandez C, Hernández-Antolín R, Escaned J, Alfonso F, Macaya C.

J Invasive Cardiol. 2004 Apr;16(4):169-74.


Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.

Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US.

Circulation. 2010 Mar 16;121(10):1188-99. doi: 10.1161/CIRCULATIONAHA.109.919456. Epub 2010 Mar 1.


Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2008 May 20;51(20):1925-34. doi: 10.1016/j.jacc.2007.12.056.


Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.

Lepäntalo A, Virtanen KS, Reséndiz JC, Mikkelsson J, Viiri LE, Karhunen PJ, Lassila R.

Thromb Res. 2009 Jun;124(2):193-8. doi: 10.1016/j.thromres.2009.01.009. Epub 2009 Feb 15.


Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.

Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, Valgimigli M; 3T/2R Investigators.

J Am Coll Cardiol. 2010 Oct 26;56(18):1447-55. doi: 10.1016/j.jacc.2010.03.103.


Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.

Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L.

J Am Coll Cardiol. 2008 Dec 9;52(24):1968-77. doi: 10.1016/j.jacc.2008.07.068.


Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.

Collet JP, Silvain J, Landivier A, Tanguy ML, Cayla G, Bellemain A, Vignolles N, Gallier S, Beygui F, Pena A, Montalescot G.

Circulation. 2008 Sep 16;118(12):1225-33. doi: 10.1161/CIRCULATIONAHA.108.776757. Epub 2008 Sep 2. Erratum in: Circulation.2008 Oct 14;118(16): e672.


Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.

Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, Bali L, Morange PE, Alessi MC, Bonnet JL.

Am J Cardiol. 2009 Oct 15;104(8):1078-82. doi: 10.1016/j.amjcard.2009.06.007.


Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA.

J Am Coll Cardiol. 2007 Feb 13;49(6):657-66. Epub 2007 Jan 26.


How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.

Neubauer H, Lask S, Engelhardt A, Mügge A.

Thromb Haemost. 2008 Feb;99(2):357-62. doi: 10.1160/TH07-10-0624.


Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.

Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, Guo YH, Cheng WJ, Jia de A, Cao Z, Nie B, Ge HL, Yang SW, Yan ZX.

Thromb Res. 2009 May;124(1):46-51. doi: 10.1016/j.thromres.2008.10.007. Epub 2008 Nov 28.


Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.

Fukushima K, Kobayashi Y, Kitahara H, Iwata Y, Nakayama T, Kuroda N, Ooyama M, Nomura F, Komuro I.

Circ J. 2008 Aug;72(8):1282-4.


Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.

Angiolillo DJ, Bernardo E, Palazuelos J, Desai B, Weisberg I, Alfonso F, Guzman LA, Hernández-Antolin R, Zenni MZ, Macaya C, Fernandez-Ortiz A, Bass TA.

Thromb Haemost. 2008 Jan;99(1):161-8. doi: 10.1160/TH07-09-0562.


Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.

Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N.

J Am Coll Cardiol. 2009 Mar 10;53(10):849-56. doi: 10.1016/j.jacc.2008.11.030.


Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.

Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, Buonamici P, Gensini GF, Vergara R, Abbate R, Antoniucci D.

J Am Coll Cardiol. 2008 Aug 26;52(9):734-9. doi: 10.1016/j.jacc.2008.05.032.


Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.

Bauriedel G, Skowasch D, Schneider M, Andrié R, Jabs A, Lüderitz B.

Am Heart J. 2003 Feb;145(2):343-8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk